Table 4.
Logit regression of concentration-mortality results of wild-type (VectoBac-12AS®) and recombinant proteins and their mixtures in A. aegypti second instar larvae at 24 h.
| Treatment (a) | Regression | LC50 Observed |
FL (95%) (b) | LC50 Expected (c) |
FL (95%) (b) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Slope ± SE | Intercept ± SE | (ng/mL) | Lower | Upper | (ng/mL) | Synergistic Factor (d) | Potency | Lower | Upper | |
| Cyt2Ba | 0.59 ± 0.13 | −3.33 ± 0.79 | 279.37 | 190.20 | 410.38 | - | - | 1 | - | - |
| Cry10Aa | 0.74 ± 0.09 | −4.26 ± 0.53 | 299.62 | 245.06 | 366.34 | - | - | 0.93 | 0.78 | 1.12 |
| Cry4Aa | 0.78 ± 0.02 | −2.77 ± 0.09 | 34.63 | 29.73 | 40.34 | - | - | 8.07 | 6.40 | 10.17 |
| Cry10Aa+Cyt2Ba (e) | 0.45 ± 0.05 | −0.64 ± 0.14 | 4.22 | 3.25 | 5.50 | 289.27 | 68.55 | 66.20 | 58.52 | 74.61 |
| Cry4Aa+Cyt2Ba (e) | 1.22 ± 0.17 | −3.17 ± 0.46 | 13.41 | 12.55 | 14.33 | 61.62 | 4.60 | 20.83 | 15.15 | 28.63 |
| VectoBac-12AS® | 1.51 ± 0.29 | 3.44 ± 0.73 | 1.02 × 10−1 | 9.34 × 10−2 | 1.11 × 10−1 | - | - | 2.73 × 103 | 2.03 × 103 | 3.69 × 103 |
(a) Inocula comprised spore+crystal mixtures. Control insects experienced no mortality in all cases. (b) FL: Fiducial limits (95%). (c) Expected LC50 calculated by the method of Tabashnik (1992). (d) Synergism factor defined as the ratio of the expected LC50 and the observed LC50. (e) Toxins were present in equal amounts in the experimental inocula.